Drug response prediction model using a hierarchical structural component modeling methodopen access
- Authors
- Kim, Sungtae; Choi, Sungkyoung; Yoon, Jung-Hwan; Kim, Youngsoo; Lee, Seungyeoun; Park, Taesung
- Issue Date
- Aug-2018
- Publisher
- BioMed Central
- Keywords
- Biomarkers; Component-based structural equation modeling; Drug response; Liver cancer; Multiple reaction monitoring mass spectrometry (MRM-MS); Prediction model; Sorafenib
- Citation
- BMC Bioinformatics, v.19, pp.1 - 12
- Indexed
- SCIE
SCOPUS
- Journal Title
- BMC Bioinformatics
- Volume
- 19
- Start Page
- 1
- End Page
- 12
- URI
- https://scholarworks.bwise.kr/erica/handle/2021.sw.erica/5699
- DOI
- 10.1186/s12859-018-2270-7
- ISSN
- 1471-2105
- Abstract
- Background: Component-based structural equation modeling methods are now widely used in science, business, education, and other fields. This method uses unobservable variables, i.e., "latent" variables, and structural equation model relationships between observable variables. Here, we applied this structural equation modeling method to biologically structured data. To identify candidate drug-response biomarkers, we first used proteomic peptide-level data, as measured by multiple reaction monitoring mass spectrometry (MRM-MS), for liver cancer patients. MRM-MS is a highly sensitive and selective method for proteomic targeted quantitation of peptide abundances in complex biological samples. Results: We developed a component-based drug response prediction model, having the advantage that it first combines collapsed peptide-level data into protein-level information, facilitating subsequent biological interpretation. Our model also uses an alternating least squares algorithm, to efficiently estimate both coefficients of peptides and proteins. This approach also considers correlations between variables, without constraint, by a multiple testing problem. Using estimated peptide and protein coefficients, we selected significant protein biomarkers by permutation testing, resulting in our model for predicting liver cancer response to the tyrosine kinase inhibitor sorafenib. Conclusions: Using data from a cohort of liver cancer patients, we then "fine-tuned" our model to successfully predict drug responses, as demonstrated by a high area under the curve (AUC) score. Such drug response prediction models may eventually find clinical translation in identifying individual patients likely to respond to specific therapies.
- Files in This Item
-
Go to Link
- Appears in
Collections - COLLEGE OF SCIENCE AND CONVERGENCE TECHNOLOGY > ERICA 수리데이터사이언스학과 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/erica/handle/2021.sw.erica/5699)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.